552 related articles for article (PubMed ID: 23702033)
1. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
Ren X; Dai M; Lin LP; Li PK; Ding J
Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
[TBL] [Abstract][Full Text] [Related]
3. Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activatio.
Wang Y; Wang B; Guerram M; Sun L; Shi W; Tian C; Zhu X; Jiang Z; Zhang L
Oncotarget; 2015 Oct; 6(30):29497-512. PubMed ID: 26470595
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
[TBL] [Abstract][Full Text] [Related]
5. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
6. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
7. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
8. Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in SGC-7901 cells and inhibits tumor growth in vivo.
Wang YR; Xu Y; Jiang ZZ; Guerram M; Wang B; Zhu X; Zhang LY
Molecules; 2015 Jan; 20(1):1661-75. PubMed ID: 25608854
[TBL] [Abstract][Full Text] [Related]
9. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the anti-angiogenesis effects induced by deoxypodophyllotoxin-5-FU conjugate C069 against HUVE cells.
Xiang R; Guan XW; Hui L; Jin YX; Chen SW
Bioorg Med Chem Lett; 2017 Feb; 27(4):713-717. PubMed ID: 28129979
[TBL] [Abstract][Full Text] [Related]
11. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin.
Komi Y; Ohno O; Suzuki Y; Shimamura M; Shimokado K; Umezawa K; Kojima S
Jpn J Clin Oncol; 2007 Nov; 37(11):867-73. PubMed ID: 17956898
[TBL] [Abstract][Full Text] [Related]
13. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
14. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
16. Vascular disrupting activity of combretastatin analogues.
Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
[TBL] [Abstract][Full Text] [Related]
17. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma.
Sun CC; Zhang YS; Xue X; Cheng YN; Liu HP; Zhao CR; Lou HX; Qu XJ
Eur J Pharmacol; 2011 Sep; 667(1-3):136-43. PubMed ID: 21704029
[TBL] [Abstract][Full Text] [Related]
19. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
20. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]